Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Low vitamin D levels were found to be associated with cardiovascular morbidity and mortality. Low zinc levels are associated with an increased atherosclerotic burden. Therefore we hypothesized that patients with pathological stress test would have low levels of Vitamin D and zinc compared to patients with a normal stress test.
| Condition |
|---|
|
Atherosclerosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test |
- positive stress test [ Time Frame: one year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
blood will be collected for vit d and zinc , stored until all samples are collected and only than the laboratoty will analyze it.
| Estimated Enrollment: | 200 |
| Study Start Date: | March 2010 |
| Estimated Study Completion Date: | March 2011 |
| Estimated Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
positive ergometry
positive ergometry as specified by a cardiologist on site.
|
|
negative ergometry.
negative ergometry as specified by cardiologist on site.
|
|
patients with positive stress test
100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
|
Detailed Description:
Hypovitaminosis D is generally defined as 25(OH)D levels of < 20ng/ml, while levels of 21-29ng/ml indicate insufficiency and those above 30ng/ml are regarded as sufficient.
The rational behind the observations associating vitamin D deficiency with CVD is that on the one hand, hypovitaminosis D was found to be associated with traditional risk factors such as hypertension (HTN),diabetes mellitus (dm),obesity, dyslipidemia and metabolic syndrome , on the other hand, experimental data demonstrated that vitamin D could affect cardiac muscle cells directly, control parathyroid (PTH) hormone secretion, regulate the rennin- angiotensin- aldosterone system and the immune system, all of which could influence cardiovascular risk.
Epidemiological studies further support this association, demonstrating high prevalence of hypovitaminosis D among U.S. adults with cardiovascular disease (74%). An association between low vitamin D levels and increased myocardial infarction risk as well as total mortality has been also observed.
Low 25hydroxyvitamin D[ 25(OH)D] levels were also independently associated with all cause and CVD mortality among patients scheduled for coronary catheterization.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
- Over 18 years old
- CCT > 60 ml/min
- No IHD
- No hyper/hypoparathyroidism
- No active malignancy
- Not taking calcium, phosphate
Inclusion Criteria:
- Over 18 years old
- CCT > 60 ml/min
- No IHD
- No hyper/hypoparathyroidism
- No active malignancy
- Not taking calcium, phosphate
Exclusion Criteria:
- Under 18 years of age
- Not fulfilling inclusion criteria
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Renana Shor MD, Assaf-Harofeh Medical Center |
| ClinicalTrials.gov Identifier: | NCT01080274 History of Changes |
| Other Study ID Numbers: | 22/10 |
| Study First Received: | March 3, 2010 |
| Last Updated: | April 6, 2010 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Assaf-Harofeh Medical Center:
|
ergometry vitamin d zinc |
Additional relevant MeSH terms:
|
Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Vitamin D Ergocalciferols |
Vitamins Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 23, 2013